National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Polo-like kinase 1 inhibitor GSK-461364
A small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:PLK-1 inhibitor GSK-461364
Code name:GSK-461364



Previous:pNGVL3-hICD vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, PNP-expressing ovine atadenovirus FP253, Pnu-Imune 23, polifeprosan 20 with carmustine implant
Next:Polo-like kinase 1 inhibitor ON 01910.Na, poly AU, poly IC, poly ICLC, poly-TLR agonist polyantigenic vaccine CADI-05

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov